Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gal Markel

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Autoimmunity Reviews|January 18, 2018
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitorsMerav Lidar, Eitan Giat, Daniela Garelick, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanomaGuy Ben-Betzalel, Erez N Baruch, Ben Boursi, et al.
Open Biology|June 13, 2014
Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complexEyal Greenberg, Steven Hajdu, Yael Nemlich, et al.
The Israel Medical Association Journal : IMAJ|October 18, 2007
Bromine--the red cloud approachingIgor Makarovsky, Gal Markel, Azik Hoffman, et al.
Cancer Immunology, Immunotherapy : CII|May 31, 2018
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patientsRonny Ben-Avi, Ronit Farhi, Alon Ben-Nun, et al.
American Journal of Surgery|December 6, 2019
The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapiesDouglas Zippel, Tal Yalon, Yehonatan Nevo, et al.
Oncotarget|January 9, 2016
Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burnsJosef Haik, Gil Nardini, Noga Goldman, et al.
Clinical Genitourinary Cancer|May 14, 2026
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell CarcinomaTomer Meirson, Luciano Mutti, Daniel A Goldstein, et al.
The Oncologist|February 20, 2019
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint InhibitorsNethanel Asher, Edith M Marom, Guy Ben-Betzalel, et al.
Immunology|June 19, 2008
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attackGal Markel, Rachel Seidman, Yifat Cohen, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Autoimmunity Reviews|January 18, 2018
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitorsMerav Lidar, Eitan Giat, Daniela Garelick, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2018
Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanomaGuy Ben-Betzalel, Erez N Baruch, Ben Boursi, et al.
Open Biology|June 13, 2014
Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complexEyal Greenberg, Steven Hajdu, Yael Nemlich, et al.
The Israel Medical Association Journal : IMAJ|October 18, 2007
Bromine--the red cloud approachingIgor Makarovsky, Gal Markel, Azik Hoffman, et al.
Cancer Immunology, Immunotherapy : CII|May 31, 2018
Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patientsRonny Ben-Avi, Ronit Farhi, Alon Ben-Nun, et al.
American Journal of Surgery|December 6, 2019
The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapiesDouglas Zippel, Tal Yalon, Yehonatan Nevo, et al.
Oncotarget|January 9, 2016
Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burnsJosef Haik, Gil Nardini, Noga Goldman, et al.
Clinical Genitourinary Cancer|May 14, 2026
Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell CarcinomaTomer Meirson, Luciano Mutti, Daniel A Goldstein, et al.
The Oncologist|February 20, 2019
Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint InhibitorsNethanel Asher, Edith M Marom, Guy Ben-Betzalel, et al.
Immunology|June 19, 2008
Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attackGal Markel, Rachel Seidman, Yifat Cohen, et al.
Pageof 14